Abstract 15591: Lowering of Lipoprotein (a) Particle Number by Lipid Apheresis
BACKGROUND: Lipid apheresis is an established therapy for lowering of LDL-C, LDL-P and other lipoproteins, but there is lack of data on reduction in Lp(a)-P with lipid apheresis. Lp(a) is a recognized risk factor for cardiovascular disease (CAD). Lp(a) measurement is affected by heterogeneity of apo (a), patients with smaller apo (a) isoforms appear to have higher risk for CAD, as compared to those with larger apo (a) isoforms. Most commercially available immunological assays are affected by this variability. Lp(a)-P measurement is not affected by this variability in apo (a) size, thus may be a better predictor of CAD risk.
OBJECTIVE: In this study we have examined the changes in Lp(a)-P levels in patients undergoing lipid apheresis.
METHODS: Lipoprotein measurements were obtained on a panel of 13 patients undergoing biweekly lipid apheresis (Liposorber, MA-03, Kaneka and HELP Futura, B.Braun) for familial hypercholesterolemia at the University of Kansas Medical Center, who were found to have elevated Lp(a)-P and CAD. Labs were drawn just before and after apheresis therapy. Paired t test was applied to assess the differences in pre and post-apheresis levels of lipoprotein measurements, and a two tailed p value was calculated. Differences in the percent reduction of different lipoproteins [LDL-C, LDL-P, Lp(a)-P and Lp(a) Mass] were assessed using one-way ANOVA test.
RESULTS: There was a significant reduction in Lp(a)-P number with apheresis (69.15±13.72). There was no statistical difference between the percent-reduction of the four different lipoproteins evaluated.
CONCLUSION: Lipid apheresis is an effective way to lower the lipoprotein (a) particle number.
- © 2013 by American Heart Association, Inc.